We are certainly due for updates on the Vaccinia trial, as we haven't heard for some time about Dose Escalation or the Cholangiocarcnoma group of patients.
As Leslie said in a recent video we are certainly looking at the right patients with the right dose and finally the durability of response.
The durability timeframe is said to be the six month mark, this is not an easy target given that we are dosing patients that are coming off 4-5 lines of prior treatment, so we are looking at patients that are thought to survive at least 3 months.
The trial exemptions mean there will be difficulties in finding patients that meet the criteria, also we are running 2 other trials looking for similar patients, although different type of cancers.
I am reminded of the old saying,"slow and steady wins the race", the cure for cancer will have many twists and turns, therefore Imugene's approach is usually the best method of undertaking trials and Yuman seems to be of the opinion that those charged with setting up the trials have done an amazing job.
If it wasnt for the concerning shareprice we would have nothing to worry about here, we are ticking along making progress and will shortly be informed of how these brave patients are progressing and our thoughts should be with them.
DYOR opinion only
IMU Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)